JP2009514507A5 - - Google Patents

Download PDF

Info

Publication number
JP2009514507A5
JP2009514507A5 JP2008522858A JP2008522858A JP2009514507A5 JP 2009514507 A5 JP2009514507 A5 JP 2009514507A5 JP 2008522858 A JP2008522858 A JP 2008522858A JP 2008522858 A JP2008522858 A JP 2008522858A JP 2009514507 A5 JP2009514507 A5 JP 2009514507A5
Authority
JP
Japan
Prior art keywords
polypeptide
nucleic acid
acid molecule
seq
isolated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2008522858A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009514507A (ja
Filing date
Publication date
Priority claimed from US11/182,942 external-priority patent/US20060019346A1/en
Application filed filed Critical
Publication of JP2009514507A publication Critical patent/JP2009514507A/ja
Publication of JP2009514507A5 publication Critical patent/JP2009514507A5/ja
Withdrawn legal-status Critical Current

Links

JP2008522858A 2005-07-18 2006-07-17 ブルシンおよびprop苦味リガンドに特異的に応答する新規苦味受容体t2r76の同定 Withdrawn JP2009514507A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/182,942 US20060019346A1 (en) 2002-07-29 2005-07-18 Identification of a novel bitter taste receptor T2R76 that specifically responds to brucine and prop bitter ligands
PCT/US2006/027656 WO2007011859A2 (en) 2005-07-18 2006-07-17 Identification of a novel bitter taste receptor t2r76 that specifically responds to brucine and prop bitter ligands

Publications (2)

Publication Number Publication Date
JP2009514507A JP2009514507A (ja) 2009-04-09
JP2009514507A5 true JP2009514507A5 (https=) 2009-07-30

Family

ID=37669462

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008522858A Withdrawn JP2009514507A (ja) 2005-07-18 2006-07-17 ブルシンおよびprop苦味リガンドに特異的に応答する新規苦味受容体t2r76の同定

Country Status (10)

Country Link
US (1) US20060019346A1 (https=)
EP (1) EP1904527A4 (https=)
JP (1) JP2009514507A (https=)
CN (1) CN101595118A (https=)
AU (1) AU2006270110A1 (https=)
CA (1) CA2610237A1 (https=)
IL (1) IL187827A0 (https=)
MX (1) MX2007015930A (https=)
NO (1) NO20076201L (https=)
WO (1) WO2007011859A2 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004011617A2 (en) * 2002-07-29 2004-02-05 Senomyx, Inc. Identification of a novel bitter taste receptor, t2r76
WO2006068745A1 (en) 2004-12-22 2006-06-29 Cargill, Incorporated Methods for determining cellular response to stimuli
WO2008008224A2 (en) 2006-07-10 2008-01-17 Duke University Sour taste receptor compositions and methods
EP2245171A2 (en) * 2008-02-01 2010-11-03 Chromocell Corporation Cell lines and methods for making and using them
US8557530B2 (en) 2008-08-29 2013-10-15 Givaudan Sa Use of a TAS2R7 nucleic acid sequence to identify modulators
CN103068380A (zh) * 2010-06-17 2013-04-24 加州理工学院 用于调节激素的方法和系统以及相关的方法、剂和组合物
HUE051738T2 (hu) 2011-01-07 2021-03-29 Anji Pharma Us Llc Kemoszenzoros receptorligandum-alapú terápiák
US9795792B2 (en) 2011-02-25 2017-10-24 Medtronic, Inc. Emergency mode switching for non-pacing modes
KR20200137035A (ko) 2012-01-06 2020-12-08 앤지 파마 유에스 엘엘씨 바이구아나이드 조성물 및 대사 장애를 치료하는 방법
EA033067B1 (ru) 2012-01-06 2019-08-30 Элселикс Терапьютикс, Инк. Способ лечения метаболических расстройств у пациента, имеющего противопоказание к назначению бигуанидного соединения
CA2878625A1 (en) 2012-07-11 2014-01-16 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
CN105101956B (zh) 2013-01-05 2018-12-07 埃尔舍利克斯治疗公司 包含双胍的延迟释放组合物
EP4566459A3 (en) * 2018-08-10 2025-08-20 Firmenich Incorporated Antagonists of t2r54 and compositions and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6004808A (en) * 1996-06-21 1999-12-21 Aurora Biosciences Corporation Promiscuous G-protein compositions and their use
JP2003057981A (ja) * 2001-08-17 2003-02-28 Nitto Kogyo Co Ltd 定着装置
WO2004011617A2 (en) * 2002-07-29 2004-02-05 Senomyx, Inc. Identification of a novel bitter taste receptor, t2r76

Similar Documents

Publication Publication Date Title
JP2009514507A5 (https=)
Comeau et al. A poxvirus-encoded semaphorin induces cytokine production from monocytes and binds to a novel cellular semaphorin receptor, VESPR
CN104059133B (zh) 一类突变的具有高耐碱特性的蛋白a及其应用
Iida et al. Interaction of Human Macrophage C-type Lectin withO-Linked N-Acetylgalactosamine Residues on Mucin Glycopeptides
WO2001055367A8 (en) Nucleic acids, proteins, and antibodies
DE69840174D1 (de) Impfstoff das mit der abmagerungskrankheit von ferkeln assoziierten circovirus typ b vorbereitet wird
Runswick et al. Mitochondrial NADH: ubiquinone reductase: complementary DNA sequence of the import precursor of the bovine 75-kDa subunit
WO2016109823A1 (en) Treatment of pediatric growth hormone deficiency with human growth hormone analogues
RU2016100732A (ru) Способы
JP2019527033A5 (https=)
Papanastasiou et al. Primary structure and biochemical properties of a variant-specific surface protein of Giardia
CN101595118A (zh) 鉴定特异应答番木鳖碱和prop苦味配体的新的苦味受体t2r76
WO2003088910A3 (en) Methods of assaying for cell cycle modulators
Stephenson et al. Identification of host insulin binding sites on Schistosoma japonicum insulin receptors
WO1999063094A3 (en) Nucleotide and protein sequences of gpr1 and methods based thereon
JP4892717B2 (ja) ニワトリキメラ抗体およびその利用
KR102236127B1 (ko) 티로시나아제를 억제하는 항-티로시나아제 항체 및 이의 용도
WO2003057827A3 (en) Insulin-responsive dna binding protein-1 and methods to regulate insulin-responsive genes
WO2002030974A2 (en) Proteins and nucleic acids encoding same
WO2001064879A2 (en) G-proteins coupled receptor related polypeptides
JP2004518410A5 (https=)
JP2001521378A (ja) アポトーシスを阻害するためのタンパク質
CA2452260A1 (en) Novel variants and exons of the glyt1 transporter
AU2006204988A1 (en) Identification of phospholipase A2 as target in cancer treatment, with special emphasis on colorectal cancer and its mechanism of action
Davis et al. Intragenic Rescue of the Function of Long QT Syndrome-Causing hERG Mutant Channels